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Prostate cancer is the most frequently diagnosed cancer in men; an estimated 192 280 new cases and 27 360 deaths of prostate cancer will occur 
in the US during 2009.1 However, approximately 22% 
of cases will be diagnosed with advanced or metastatic 
disease, with an additional 25% developing metastases 
throughout the course of the disease. The majority of 
prostate cancers initially respond to hormone therapy, 
with median response duration in metastatic disease 
of around 18 months. However, in most patients the 
cancer will become resistant to hormonal treatment and 
will progress. After developing hormonelresistant disl
ease, survival is not expected to exceed 9 to 12 months. 
Treatment for HRMPC is palliative.2 The options 
include symptomatic care with narcotic analgesics, ral
diotherapy to dominant sites of bone pain, treatment 
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BACKGROUND AND OBJECTIVES: since previous studies have indicated there are improvements in overall 
survival, the aim of this phase ii clinical study was to evaluate docetaxel every three weeks plus prednisone as 
first-line chemotherapy for treatment of hormone-refractory metastatic prostate cancer (hrmpc).
METHODS: thirty-five metastatic hrpc patients were treated with docetaxel 70 mg/m2 every 3 weeks plus oral 
prednisolone 5 mg twice daily at the clinical oncology departments of tanta, mansoura and menofia university 
hospitals during the period from June 2006 to december 2008. the primary endpoint was assessment of the 
overall tumor response rate. secondary endpoints were assessment of psa response rate, overall survival rate, 
and the time to disease progression.
RESULTS: the median number of cycles administered was 6 cycles. partial response was observed in 15 patients 
(42.9%) with evaluable measurable disease. median survival from protocol entry was 15 months. median time-
to-disease progression was 10 months. prostate-specific antigen (psa) declined ≥50% in 9 patients (25.7%). the 
most common grade 3/4 toxicity associated with studied protocol was neutropenia (85.7%).
CONCLUSIONS: When given with prednisone, treatment with docetaxel every three weeks does not improve 
survival, so the benefit of docetaxel-based therapy is not clear this high risk and poor prognostic group of pa-
tients.
with bonelseeking isotopes such as strontiuml89, and 
cytotoxic chemotherapy. 3
Prostate cancer was considered resistant to chemol
therapy until the midl1990s, when mitoxantrone with 
prednisone (MP) was shown in a Canadian study to 
have a role in the palliative treatment of HRMPC.2 
Men with HRMPC experienced an improvement in 
pain and QOL if treated with MP compared with predl
nisone alone. No survival benefit was detected in trials 
comparing mitoxantrone plus corticosteroids with corl
ticosteroids alone, although the studies were not powl
ered to detect small differences in survival.4,5 
In 2004, reports of the TAX 327 and Southwest 
Oncology Group 99l16 studies showed significant 
survival benefit when docetaxellbased treatment 
was compared with mitoxantrone for men with 
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HRMPC.6,7 In 2007 Shimazui et al in a retrospective 
Japanese study concluded that a regimen of 70 mg/m2 
of docetaxel every 3 weeks and 10 mg/day of prednil
sone given orally had a favorable outcome with high rate 
of prostate specific antigen (PSA) reduction and an 
acceptable number of adverse events.8 
Docetaxel, a semilsynthetic taxoid, disrupts the 
cellular microtubular network, promoting assembly 
of stable microtubules and inhibiting disassembly. 
The recommended dose of docetaxel for phase II tril
als was 70 mg/m2 in minimally pretreated patients.9 
Docetaxel was approved by the US Food and Drug 
Administration and is currently a promising treatment 
for patients with HRMPC.
Since 2004 and the first improvement in overall 
survival in HRMPC brought about by docetaxel, nul
merous phase II and III studies have been initiated. 
Considering the lack of efficacy in terms of overall 
survival, hormonal manipulations such as antiandrol
gen withdrawal, diethylstilbesterol or dexamethasone 
are only indicated in patients with rising PSA without 
clinical or radiological evidence of metastases. As first 
line treatment, the optimal chemotherapy regimen is 
docetaxel (75 mg/m2 every 3 weeks) in association with 
prednisone (5 mg twice daily). Second line chemotheral
pies (mitoxantron, ixabepilon, docetaxel as a reltreatl
ment, vinorelbine, doxorubicin) provide modest results 
only in terms of progressionlfree survival.10
PATIENTS AND METHODS
This prospective, phase II multicenter study included 
35 patients with HRPMC. Those patients had been 
treated inclusively by a regimen of docetaxel and predl
nisone in the clinical oncology departments of Tanta, 
Mansoura and Menofia University Hospitals during 
the period from June 2006 to December 2008. The age 
of the patients ranged from 52 to 73 years, with the 
mean age of 65.3±5.14 years. 
Eligibility criteria included histologically proven 
metastatic adenocarcinoma of the prostate with prol
gressive disease, despite androgen deprivation. Disease 
progression for HRPC patients was defined as apl
pearance of new lesion(s), and/or an increase of >25% 
of measurable metastases, and/or the appearance of 
new foci on a radionuclide bone scan, and/or three 
consecutive increases in PSA concentration at least 
1 week apart in the presence of testosterone castrate 
level of metastatic patients. Other eligibility criteria inl
cluded no prior chemotherapy, an Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) of 
0 to 2, and at least 4 weeks since completion of radial
tion. Antiandrogen withdrawal and subsequent docul
mented disease progression was required before study 
entry (at least 4 weeks since prior flutamide, cyprotrone 
acetate or baclutamide and 6 weeks since prior bicalul
tamide). Patients were required to have a castrated level 
of testosterone (<50 ng/mL) achieved by bilateral orl
chidectomy or administration of luteinizinglhormone 
releasing hormone agonist. Patients were excluded for 
uncontrolled diabetes and all comorbid conditions that 
might limit survival. Patient written consent was obl
tained in every case. Radiological investigations, includl
ing radionuclide bone scan, CT scan of the abdomen 
and pelvis, and chest xlray were performed preltreatl
ment as baseline and at a minimum every 12 weeks. 
Physical examinations and laboratory studies included 
CBC, serum chemistry profile, testosterone, and PSA 
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Figure 1. Overall survival for all patients.
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Figure 2. Progression-free survival for all patients.
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were performed preltreatment and at a minimum every 
4 weeks. Patients were required to meet the following 
hematological criteria prior to commencement of each 
treatment cycle: neutrophil count >2000 µL; hemoglol
bin above 10 g/dL and a platelet count above 100×103/
µL; total serum bilirubin of ≤1.5 times of institutional 
upper limit of normal level (ULN); aspartate and alal
nine aminotransferase levels ≤1.5 times ULN; creatil
nine levels ≤1.5 times ULN; alkaline phosphatase less 
than 2 times ULN. 
Patients received docetaxel 70 mg/m2 administered 
as ≥1lhour intravenous infusion every 3 weeks plus 
oral prednisolone 5 mg twice daily starting on Day 1 
and continuing throughout treatment. Treatment was 
planned for 10 cycles; for those patients who had a conl
tinued clinical benefit beyond 10 cycles, entry into a sepl
arate clinical study of extended therapy was permitted. 
Patients continued to receive prednisolone in the event 
of withdrawal from the study and after completion. In 
the event of prednisolone discontinuation, the dose 
was tapered to avoid withdrawal syndrome. The dose 
of docetaxel was reduced by 10 mg/m2 in subsequent 
treatment cycles if any of the following criteria were 
met: 3/4 grade hematological toxicity, thrombocytopel
nia; or grade 3/4 nonlhematological toxicity (including 
neurotoxicity, nausea and/or vomiting, infection or all
lergic reaction). Dose reduction or cessation of predl
nisolone administration was considered in cases of pepl
tic ulcer, posterior subcapsular cataract, glaucoma, and 
infection. Patients were removed from protocol therapy 
for a treatment delay greater than 3 weeks or recurl
rence of the same grade ≥3 toxicities despite two dose 
reductions. However, treatment continued until disease 
progression occurred. Granulocyte colonylstimulating 
factor (GlCSF) could be administered during any cycle 
in which the neutrophil count was <1000 ×106 cells/L 
in the presence of fever (≥38.8C) or <500×106 cells/L 
in the absence of fever. Prophylactic antilemetics, antil
histamines and corticosteroids could be administered if 
required. Patients who progressed after at least 2 cycles 
of protocol treatment or who stopped treatment for 
toxicity or other medical reasons were eligible to receive 
the alternate treatment.
The primary endpoint was the overall tumor rel
sponse rate, assessed with WHO guidelines.11 Overall 
tumor response (measured by visceral and/or softltisl
sue assessment, primary prostate lesion assessment, and 
bone scan) was assessed at cycles 2, 6 and 10, and to 
confirm response. Secondary endpoints were PSA rel
sponse rate, overall survival rate, the time to disease prol
gression (TDP)  and assessment of pretreatment progl
nostic factors. PSA decline (≥50%) was documented in 
Table 1. Baseline characteristics of patients with HRMPC.
Characteristics n=35 %
Age
   Years
     < 60 5 14.3
     61-70 22 62.9
     >70 8 22.8
   Range 52-73
   Median 65 
   SD ± 5.14
PSA 
   <50 ng/Ml 14 40
   >50 ng/Ml 21 60
   Range 20.0 -  2148.0 ng/Ml   
   Mean  331.3 ng/ Ml
Performance status 
   I 18 51.4
   II 17 48.6
Gleason score
   2-4 1 2.9
   5-7 14 40.0
   8-10 20 57.1
Metastatic sites
   Bone only 26 74.3
   Bone and soft tissue 9 25.7
Number of bone metastases
   <6 13 37.1
   >6 22 62.9
Time since diagnosis of metastatic 
prostate cancer
   1-2 year 14 40.0
   >2-3 years 17 48.6
   > 3 years 4 11.4
Previous treatment
   Casteration + flutamide  18 51.43
   Casteration + cyproterone 
   acetate  11 31.43
   Goserelin + fluamide  2 5.71
   Goserelin  + biclutamide 4 11.43
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to 6 weeks from the last administration of docetaxel 
and were evaluated according to The Common Toxicity 
Criteria (CTC).13 
This phase II study was planned to accrue a total 
of 35 patients. Data was analyzed using the SPSS 10 
statistics database. Patient characteristics were suml
marized by descriptive statistics (median, range and 
frequency).The percentage of patients experiencing 
clinical response (PR) was reported along with the 
corresponding exact 95% confidence intervals (CI).14 
Kaplan–Meier curves15 (with 95% CI) were plotted for 
OS and PFS. Univariate analysis of preltreatment facl
tors and treatment response on median timeltoldisease 
progression and median overall survival was performed 
and statistical significance assessed by the loglrank test. 
The P value of ≤.05 was considered significant.
RESULTS
A total of 202 cycles of treatment were administered to 
35 patients (median 6 cycles per patient [range 2–10]) 
as firstlline treatment. Eightylfive percent of patients 
received at least 5 cycles of therapy. Patient baseline 
characteristics are detailed in Table 1.
The overall tumor response rate (PR plus SD) was 
74.3% (95% CI equal 57.95 to 85.85); all responses 
were partial responses (PR) as none of studied patients 
had achieved complete response. Stable disease was 
observed in 11 patients (31.4%). The disease had been 
progressed in 9 patients (25.7%) with a median dural
tion of response was 16.2 weeks (Table 2). 
PSA response was seen in 24 (68.6%) of patients, 
with ≥50% reduction of the baseline level had ocl
curred in 9 (25.7%) patients and <50% reduction of the 
baseline level had occurred in 15(42.9%) patients. The 
median duration of PSA response was 16 weeks. PSA 
level had progressed in 11 (31.4%) and the median time 
to PSA progression was 20.4 weeks (Table 3).
The median overall survival time for all patients was 
15 months (with 95% CI of 12.4 to 17.6 and standard 
error of 1.3). The median timeltoldisease progression 
for all patients was 10 months (with 95% CI equal 8.4l
11.9 and standard error of 0.98) and mean time was 8.9 
months (Table 3). A univariate analysis of pretreatment 
factors (including age, the initial serum PSA levels, the 
GS, the number of bone metastases and the type of mel
tastases) and treatment response that influence the mel
dian overall survival showed that pretreatment factors 
had no significant impact on OS and TDP. (Table 4). 
Both hematological and nonlhematological toxicil
ties were reported for all 35 patients (100%) (Table 5). 
The most common grade 3/4 hematological toxicity 
was neutropenia (85.7%). Four patients (11.4%) devell
accordance with the consensus guidelines of the PSA 
Working Group.12 The timeltolPSA progression was 
measured from the date of start of treatment to the date 
of PSA progression and was defined by a ≥25% inl
crease in PSA level from baseline or a ≥50% increase in 
PSA level from the lowest value achieved, provided that 
the increase was at least 5 ng/mL, confirmed by three 
successive measurements at 3lweek intervals. The dul
ration of PSA response was the time interval between 
the dates of the first 50% decline in PSA until PSA 
increased to 50% above the nadir. Overall survival was 
defined as the time between study entry and death or 
date of last followlup. Treatment toxicities were collectl
ed from the first administration of docetaxel through 
Table 2. Best overall tumor response by WHO response criteria 
(primary endpoint).
Response No. %
CR 0 0.00
PR 15 42.9
SD 11 31.4
Progressive disease 9 25.7
Overall tumor response 
(PR+SD), (95% CI)   26
74.3
(57.95 to 85.85)
Table 3. Secondary end points.
Secondary end 
points
95% 
Confidence 
interval
Standard 
error
PSA response 
(n [%])
  ≥50% reduction 9 (25.7)
14.2 – 42.1  <50% reduction 15 (42.9)
  Progressive 
  elevated 11 (31.4)
Overall survival 
(months)
  Range 4-24
  Median 15 12.4-17.6 1.3
  Mean 15.3 12.9-17.6 1.2
Time to disease 
progression 
(months)
  Range 2-14
  Median 10 8.4-11.9 0.98
  Mean 8.7 7.4-10.1 0.7
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oped anemia while grade 3/4 thrombocytopenia was 
not recorded. Five patients (14.3%) developed febrile 
neutropenia and infection (chest infection), and were 
treated with antibiotics, growth factors and antipyretl
ics. The most common grade 3/4 nonlhematological 
event was sensory neuropathy (11.4%) followed with 
nausea and/or vomiting (5.7%) and infection without 
neutropenia (5.7%). Grade I and II edema occurred 
in 4/35 (11.4%) patients. Adverse events that led to 
the discontinuation of treatment included sensory 
neuropathy and infection. No treatmentlrelated deaths 
were recorded.
DISCUSSION
Historically, prostate cancer has been a chemoresisl
tant disease with earlier trials showing disappointing 
response rates (<20%). However, in 1996 Tannock et 
al published the first evidence of the palliative benefit 
of mitoxantrone and prednisolone over prednisolone 
alone in patients with symptomatic MHRPC in a ranl
domized trial.4 Subsequent studies confirmed the same 
results but failed to a show a survival benefit for chel
motherapy, until 2004 in two landmark studies (TAXl
327and SWOG 99l16) that provided the first evidence 
of survival benefit with docetaxellbased chemotherapy 
for patients with MHRPC.6,7 In the TAX 327 study, 
1006 men with MHRPC received prednisolone 5 mg 
twice daily and were randomized to receive mitoxanl
trone 12 mg/m2 every three weeks, docetaxel 75 mg/m2 
every three weeks, or docetaxel 30 mg/m2 weekly for 
five out of every six weeks. This study confirmed the sul
periority of the an every three weeks docetaxel regimen 
over mitoxantrone with a significant improvement in 
median survival (18.9 vs. 16.5 months; P=.009), PSA 
response (45 vs. 32%; P<.001) and pain response (35 
vs. 22%; P=.01). 
In the SWOG 99l16 trial, 770 men were randoml
ized to receive either estramustine 280 mg orally threel
times daily on Days 1l5 of a 3lweek cycle, docetaxel 
60 mg/m2 on Day 2 or mitoxantrone 12 mg/m2 on 
Day 1 plus prednisone 5 mg daily. Median overall surl
vival was significantly longer among patients treated 
with docetaxellestramustine compared with those 
receiving mitoxantronelprednisone (17.5 versus 15.6 
months, respectively; P=.02). The median timeltol
progression was 6.3 months for docetaxellestramusl
tine and 3.2 months in the mitoxantronelprednisone 
group. Based on the results of these studies, the 
National Institute for Health and Clinical Excellence 
(NICE) committee approved ten cycles of three week 
docetaxel chemotherapy (75 mg per m2) in combinal
tion with prednisolone 10 mg daily as standard of care 
Table 4. A univariate analysis of pre-treatment factors and treatment response on 
median time to disease progression and median overall survival.
Prognostic  variables No. (%)
Median 
time
to disease 
progression 
(months)
P
Median 
overall 
survival P
Age in years
   ≤ 65 17 (48.6) 10
.24
19
.35
   > 65 18 (51.4) 8 14
Performance status
   I 18 (51.4) 10 .053 20 .13
   II 17 (48.6) 9 10
Initial PSA level
   ≤50 ng/ml 14 (40) 10
.28
19
.22
   >50 ng/ml 21 (60) 8 14
Gleason score
   ≤7 15 (42.9) 10
.07
20
.27
   >7 20 (57.1) 8 15
Bone metastases
   <6 13 (37.1) 10
.69
18
.87
   ≥6 22 (62.9) 8 14
Metastatic sites
   Bone only 26 (66.7) 9 .43 16 .38
   Bone & soft tissue 9 (33.3) 10 10
Treatment response  
   PRa 15 (42.9) 11 .28 (a vs. b) 22
.008
(a vs. b)
   SDb 11(31.4) 9 .006(b vs. c) 14
.059 
(b vs. c)
   Progressive 
   diseasec 9 (25.7) 2
.00001
(a vs. c) 8
.0001
(a vs. c)
P ≤.05 is considered significant. 
for firstlline chemotherapy in patients with HRMPC.16 
The primary endpoint in the present study was overl
all tumor response rate. The overall tumor response rate 
(PR + SD) of 74.3% with no patients had achieving 
CR. These results compare favorably with that reported 
with Naito et al 200817 in a phase II Japanese study that 
included 43 patients with HRMPC, and had an overl
all tumor response rate was 76.7%. On the other hand, 
Zhang et al 200718 reported a tumor response rate of 
72.6% (13.6% CR, 29.5% PR, 29.5% SD and 27.4% 
progressive disease). 
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Table 5.  Treatment-related adverse events.
Any grade Grade 3-4
No. % No. %
Neutropenia 34 97.1 30 85.7
Febrile neutropenia 5 14.3 5 14.3
Anemia 29 82.9 4 11.4
Thrombocytopenia 7 20.0 0 0
Alopecia 22 62.8 3 8.6
Nausea and/or vomiting 15 42.8 2 5.7
Anorexia 7 20.0 0 0.0
Neuropathy 10 28.6 4 11.4
Fatigue 12 34.3 0 0.0
Diarrhea 9 25.7 0 0.0
Infection 5 14.3 2 5.7
Nail toxicity 4 11.4 0 0
Edema 4 11.4 0 0
 The secondary end points in this study were PSA 
response, overall survival time and timeltoldisease prol
gression. In our study, the PSA response rate ≥50% 
reduction of the base line level was 42.9%. Shimazui 
et al 2007,8 reported an overall PSA response rate of 
68.8%. Our results were comparable with Naito et al 
2008, 17 Tannock et al 20046 (44.4% and 45% respecl
tively); on the other hand, Saad et al 200819 and Ansari 
J et al 2008,20 reported higher response rates (57% and 
54% respectively).
In our study the median survival time was 15 months. 
The overall survival time was lower than that reported 
by Tannock et al 2004.6 The TAX 327 trial confirmed 
the superiority of the threelweek docetaxel regimen 
over mitoxantrone with a significant improvement in 
median survival (18.9 vs. 16.5 months; P=.009), probl
ably because the patient population in the present study 
had worse characteristics than in the TAX 327 trial. 
In our study the median timeltoldisease progression 
and the median survival time were 10 and 15 months. 
respectively. Shimazui et al 20078 reported a median 
timeltoldisease progression of 8.5 months and median 
overall survival of 12.5 months. Saad et al 200819 rel
ported a median progressionlfree and overall survival of 
5 and 15 months, respectively and Ansari J et al 200820 
reported a median overall survival was 13 months. 
However, Howard et al 2008,21 reported in a retrospecl
tive study from Canada that among 161 patients with 
HRMPC, docetaxel and prednisone did not perform as 
well in terms of median survival (17.2 months), as it was 
shown to in prior clinical trials (17.2 vs. 18.9 months). 
Most of the adverse events observed in our study were 
predictable and manageable. The incidence of grade 3/4 
neutropenia was 85.7%; only 5 of 35 patients (14.3%) 
had febrile neutropenia. Adverse events required a dose 
reduction in only 18 of 202 cycles (8.9%). The usage 
of GlCSF occurred in 63 of 202 cycles (31.2%). There 
were no deaths during the study or within 30 days of 
the last dose of study medication. Lin et al 200722 rel
ported that longlterm adverse effects associated with 
continuous docetaxel treatment include asthenia, edel
ma, peripheral neuropathy and cytopenia. In the TAX 
327 study, while the 3lweekly docetaxel regimen was 
associated with grade 3/4 neutropenia in only 32% of 
patients.6 Naito et al 200813 reported 93% grade 3/4 
neutropenia with 16.3% of patients developed febrile 
neutropenia. Shimazui et al 20078 reported 75% grade 
3/4 neutropenia with 12.5% febrile neutropenia and 
Numata et al 200723 found 78% grade 3/4 neutropenia 
and only one patient with febrile neutropenia. 
In conclusion, our data suggest that docetaxel 70 
mg/m2 every 3 weeks and daily oral prednisolone 10 
mg does not improve survival, so the benefit of docetaxl
ellbased therapy is not clear in this high risk and poor 
prognostic group of patients.
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